Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | HTT | P42858 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | CTSL | P07711 | 1/20 | 0.33 |
| ▸ | PTPRC | P08575 | 1/20 | 0.33 |
| ▸ | PTPN13 | Q12923 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3960477 | 0.87 | KMT2A (0.35) | TSHRALDH1A1LMNAHTTMAPT | |
| SCHEMBL7180513 | 0.85 | CYP4F2 (0.36) | TSHRALDH1A1LMNAMAPTKMT2A | |
| SCHEMBL4447139 | 0.79 | — | — | |
| SCHEMBL3958590 | 0.77 | GAA (0.41) | TSHRALDH1A1MAPTKMT2AKDM4E | |
| SCHEMBL5160584 | 0.77 | — | — | |
| SCHEMBL7516468 | 0.77 | — | — | |
| SCHEMBL16014041 | 0.76 | CRHBP (0.41) | TSHRLMNAMAPTKMT2AHSD17B10 | |
| SCHEMBL2572905 | 0.76 | MEN1 (0.31) | KMT2A | |
| SCHEMBL11002171 | 0.76 | LMNA (0.40) | TSHRALDH1A1LMNAHTTMAPT | |
| SCHEMBL3962659 | 0.76 | PTPRC (0.30) | PTPRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6921822-B2 | Process for stereoselectively reducing 4-aryl-4-oxobutanoic acid derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2005-07-26 | — | — | US | claimed |
| US-20040030181-A1 | Process for stereoselectively reducing 4-aryl-4-oxobutanoic acid derivatives | LANXESS DEUTSCHLAND GMBH (DE) | 2004-02-12 | — | — | US | claimed |
| EP-1369410-A1 | Process for the stereoselective reduction of derivatives of 4-aryl-4-oxobutyric acid | BAYER AG (DE) | 2003-12-10 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040030181-A1 | Process for stereoselectively reducing 4-aryl-4-oxobutanoic acid derivatives | HPD, GRHPR, CYP4B1 | TSHR 3656/4885ALDH1A1 133/4885LMNA 4644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.